1. Clinical & Scientific Overview
Codeine Phosphate (TIP-MED-000524, Reference Code [R-05]) is classified under
Narcotic Analgesics & Antitussives as a Phenanthrene Opioid Agonist & Central Antitussive.
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 & NDPS Manufactured Narcotic Drug.
Codeine Sulfate Tablets (Rusan Pharma), Codistar-DX Reformed Reference (Monotherapy Codeine Controlled)
Oral Tablet: 15 mg, 30 mg; Linctus (Restricted Hospital Supply): 10 mg/5 mL
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule H1 & NDPS Manufactured Narcotic Drug
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: CYP2D6 ultra-rapid metabolisers convert codeine rapidly into toxic morphine concentrations, causing life-threatening respiratory depression; strictly contraindicated in children <12 years, post-tonsillectomy/adenoidectomy (<18 years), and breastfeeding mothers.
Mandatory Dispensing Register & Institutional Custody Protocol: Verify patient age (>=12 years) and non-lactating status; log in Schedule H1 register.
3. Mechanism of Action & Pharmacodynamics
Prodrug O-demethylated by hepatic CYP2D6 (~10%) to morphine, which binds mu-opioid receptors; exhibits direct medullary cough-centre suppression.
4. Therapeutic Indications & Evidence-Supported Uses
- Severe non-productive cough refractory to non-opioid antitussives
- Mild-to-moderate acute pain in adults
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Codeine Phosphate must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Oral Tablet: 15 mg, 30 mg; Linctus (Restricted Hospital Supply): 10 mg/5 mL).
Administration & Meal Timing: Routes: Oral. Verify patient age (>=12 years) and non-lactating status; log in Schedule H1 register.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits phenanthrene opioid agonist & central antitussive pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Codeine Phosphate or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: CYP2D6 ultra-rapid metabolisers convert codeine rapidly into toxic morphine concentrations, causing life-threatening respiratory depression; strictly contraindicated in children <12 years, post-tonsillectomy/adenoidectomy (<18 years), and breastfeeding mothers.
8. Adverse Effects Profile
- CYP2D6 ultra-rapid metabolisers convert codeine rapidly into toxic morphine concentrations, causing life-threatening respiratory depression; strictly contraindicated in children <12 years, post-tonsillectomy/adenoidectomy (<18 years), and breastfeeding mothers.
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- CYP2D6 ultra-rapid metabolisers convert codeine rapidly into toxic morphine concentrations, causing life-threatening respiratory depression; strictly contraindicated in children <12 years, post-tonsillectomy/adenoidectomy (<18 years), and breastfeeding mothers.
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CYP2D6 ultra-rapid metabolisers convert codeine rapidly into toxic morphine concentrations, causing life-threatening respiratory depression; strictly contraindicated in children <12 years, post-tonsillectomy/adenoidectomy (<18 years), and breastfeeding mothers.
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Verify patient age (>=12 years) and non-lactating status; log in Schedule H1 register.
Pharmacist Patient Counselling Points:
- Verify patient age (>=12 years) and non-lactating status; log in Schedule H1 register.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Verify patient age (>=12 years) and non-lactating status; log in Schedule H1 register.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.